NCT04899232

Antithrombin III in Infectious Disease Caused by COVID-19

Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: Enrique Ginzburg · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to see if participants who have SARS-CoV-2 and low levels of AT3 in the blood will benefit by being given AT3.

Conditions

• Antithrombin III Deficiency
• Covid19

Interventions

Type	Name	Description
DRUG	Antithrombin III	Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).

Timeline

• Start date: 2021-07-06
• Primary completion: 2022-03-31
• Completion: 2022-03-31
• First posted: 2021-05-24
• Last updated: 2022-09-07
• Results posted: 2022-09-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study